Table 1. Resistance to first- and second-line antituberculosis drugs.
| New cases (N = 1174) | Re-treated cases (N = 597) | |||
|---|---|---|---|---|
| n (%) | 95% CI | n (%) | 95% CI | |
| Susceptibility to all four first-line drugs † | 796 (67.7) | 65.1–70.4 | 280 (47.0) | 43.0–51.0 |
| Any resistance to first-line drugs | 378 (32.3) | 29.6–34.9 | 317 (53.0) | 49.0–57.0 |
| Isoniazid (INH) | 202 (17.3) | 15.1–19.4 | 218 (36.4) | 32.5–40.3 |
| Rifampin (RMP) | 125 (10.6) | 8.9–12.4 | 172 (28.9) | 25.2–32.5 |
| Ethambutol (EMB) | 52 (4.4) | 3.2–5.6 | 70 (11.9) | 9.2–14.3 |
| Streptomycin (SM) | 310 (26.4) | 23.9–28.9 | 233 (39.1) | 35.2–43.0 |
| Resistance to INH or RMP | 126 (11.7) | 9.8–13.7 | 113 (24.6) | 20.7–28.6 |
| Multidrug resistance (MDR) ‡ | 101 (8.6) | 7.0–10.2 | 138 (23.2) | 19.8–26.5 |
| Susceptibility to ofloxacin (OFX) and kanamycin (KM) | 1084 (92.3) | 90.7–93.8 | 505 (84.7) | 81.8–87.6 |
| Any resistance to OFX or KM | 91 (7.7) | 6.2–9.3 | 91 (15.3) | 12.4–18.2 |
| OFX resistance | 66 (5.6) | 4.3–6.9 | 68 (11.4) | 2.7–4.8 |
| KM resistance | 44 (3.7) | 2.7–4.8 | 43 (7.2) | 5.1–9.3 |
| MDR + resistance to OFX or KM | 64 (5.6) | 4.2–6.9 | 74 (12.8) | 10.0–15.5 |
| Extensive drug resistance ¥ | 14 (1.2) | 0.6–1.8 | 15 (2.5) | 1.3–3.8 |
† First-line antituberculosis drugs include isoniazid, rifampin, ethambutol, and streptomycin; second-line antituberculosis drugs include ofloxacin and kanamycin.
‡ Multidrug resistance was defined as resistance to at least isoniazid and rifampin.
¥ Extensive drug resistance was defined as resistance to at least isoniazid, rifampin, ofloxacin, and kanamycin.